Steven T. Chen

Steven T. Chen

Auto-generated profile, based on publicly available information

Steven T. Chen

Department of Dermatology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2019 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Open access
PDF file
RYRebecca L. Yanovsky
Rebecca L. Yanovsky
DBDiana W. Bartenstein
Diana W. Bartenstein
GRGary S. Rogers
Gary S. Rogers
SISteven J. Isakoff
Steven J. Isakoff
SCSteven T. Chen
Steven T. Chen
Photodynamic therapy (PDT) utilizes a sensitizer agent and light to produce selective cell death. Dermatologists are familiar with PDT for the treatment of actinic keratoses and early nonmelanoma skin cancers, and recent studies have elucidated that PDT has resulted in improved morbidity and secondary outcomes for the treatment of various cancerous and precancerous solid tumors. Light source and dosimetry may be modified to selectively target tissue, and novel techniques such as fractionation, metronomic pulsation, continuous light delivery, and chemophototherapy are under investigation for further optimization of therapy. This article aims to review the expanding indications for PDT and demonstrate the potential of this modality to decrease morbidity and increase quality of life for patients. To illustrate these new indications, we provide a focused review of the latest literature on PDT for dermatologic and other solid tumors including gastrointestinal, peritoneal, lung, genitourinary, brain, breast, and head and neck. Data on efficacy, survival, and side effects vary across tumor types but support PDT for the treatment of numerous solid tumors. With new advances in PDT, indications for this therapeutic modality may expand.

12 January 2013 in Current Dermatology Reports
Verified
Journal Article
Closed access
PDF file
SCSteven T. Chen
Steven T. Chen
AGAlan C. Geller
Alan C. Geller
HTHensin Tsao
Hensin Tsao

1 May 2021 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
LTLeah L. Thompson
Leah L. Thompson
NKNira A. Krasnow
Nira A. Krasnow
MCMichael S. Chang
Michael S. Chang
JYJaewon Yoon
Jaewon Yoon
ELEdward B. Li
Edward B. Li
SCSteven T. Chen
Steven T. Chen
Importance Cutaneous immune-related adverse events (cirAEs) are some of the earliest toxic reactions to emerge following immune-checkpoint inhibitor (ICI) initiation. As an early indicator of robust inflammatory response, cirAEs may be associated with patterns of immune-mediated toxic effects, but associations between these events and noncutaneous immune-related adverse events (irAEs) remain underexplored. Objectives To characterize patterns of cirAEs and irAEs across care settings and examine associations between the features of first cirAE, overall irAE risk, and risk of specific irAE subtypes. Design, Setting, and Participants A retrospective cohort study was conducted at a single academic medical center. The cohort included 358 patients with cancer who initiated anti–programmed death 1/ligand 1 and/or anticytotoxic-T-lymphocyte-4 ICI therapy between January 1, 2016, and March 8, 2019, and developed 1 or more cirAEs, identified usingInternational Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and confirmed via manual medical record review. All relevant information documented before March 31, 2020, was included. Exposures Anti–programmed death 1/ligand 1 and/or anticytotoxic-T-lymphocyte-4 therapy. Main Outcomes and Measures Associations between specific cirAE morphologic classes and patterns of irAEs (occurrence, timeline, organ class, and specific toxic effects). Given the potential that shared underlying factors are associated with the risk of both noncutaneous and cutaneous toxic effects, the presence of observed positive associations between certain cirAE and irAE subtypes was hypothesized. Results Of the 358 patients, 213 were men (59.5%); median age was 65 years (interquartile range, 55-73 years). Nearly half of the patients (177 [49.4%]) with cirAE also developed a noncutaneous irAE. Most patients (128 [72.3%]) experienced their first cirAE before developing any irAE. Several cirAE morphologic classes were found to be associated with overall, organ-based, and specific irAEs. More specifically, mucositis was found to be associated with overall irAE risk (odds ratio [OR], 5.28; 95% CI, 1.11-24.26;P = .04), gastrointestinal irAEs (OR, 5.70; 95% CI, 1.11-29.40;P = .04), and the specific diagnosis of gastroenterocolitis (OR, 6.80; 95% CI, 1.24-37.39;P = .03). In addition, psoriasis was associated with an increased risk of endocrine irAEs (OR, 4.54; 95% CI, 1.21-17.04;P = .03). Conclusions and Relevance In this cohort study, these findings underscore the risk of multisystem toxic effects in patients experiencing cirAEs and highlight potential opportunities for dermatologists in the management of noncutaneous toxic effects.

1 November 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
GMGabriel E. Molina
Gabriel E. Molina
ZYZizi Yu
Zizi Yu
RFRuth K. Foreman
Ruth K. Foreman
KRKerry L. Reynolds
Kerry L. Reynolds
SCSteven T. Chen
Steven T. Chen

1 March 2018 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
SCSeverine Cao
Severine Cao
ELEvelyn Lilly
Evelyn Lilly
SCSteven T. Chen
Steven T. Chen
Hailey-Hailey disease (HHD) is a genetic intraepidermal blistering disorder characterized by chronic macerated erosions in intertriginous areas.1 The recent report of 2 case series2,3 demonstrating the efficacy of low-dose naltrexone in the treatment of HHD represents exciting progress in the management of a disease with limited therapeutic options. Herein we present 3 additional cases of HHD demonstrating varying responses to naltrexone.

12 June 2020 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
GMG.E. Molina
G.E. Molina
KRK.L. Reynolds
K.L. Reynolds
SCS.T. Chen
S.T. Chen